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Thalidomide and its derivatives, lenalidomide and pomalidomide (also
known as IMiDs), have significantly changed the treatment landscape of
multiple myeloma, and the recent discovery of cereblon (CRBN) as their
direct biological target has led to a deeper understanding of their complex
mechanism of action. In an effort to comprehend the precise mechanisms
behind the development of IMiD resistance and examine whether it is
potentially reversible, we established lenalidomide-resistant (-LR) and
pomalidomide-resistant (-PR) human myeloma cell lines from two IMiD-
sensitive cell lines, OPM2 and NCI-H929, by continuous culture in the
presence of lenalidomide or pomalidomide for 4–6 months, until acquire-
ment of stable resistance. By assessing genome-wide DNA methylation and
chromatin accessibility in these cell lines, we found that acquired IMiD
resistance is associated with an increase in genome-wide DNA methylation
and an even greater reduction in chromatin accessibility. Transcriptome
analysis confirmed that resistant cell lines are mainly characterized by a
reduction in gene expression, identifying SMAD3 as a commonly downreg-
ulated gene in IMiD-resistant cell lines. Moreover, we show that these
changes are potentially reversible, as combination of 5-azacytidine and
EPZ-6438 not only restored the observed accessibility changes and the
expression of SMAD3, but also resensitized the resistant cells to both
lenalidomide and pomalidomide. Interestingly, the resensitization process
was independent of CRBN. Our data suggest that simultaneous inhibition
of DNA methyl transferases and EZH2 leads to an extensive epigenetic
reprogramming which allows myeloma cells to (re)gain sensitivity to
IMiDs.
Abbreviations
CRBN, cereblon; DNMT1, DNA methyl transferase 1; dscDNA, double-stranded cDNA; MM, multiple myeloma; MS-MCA, methylation-
specific melting curve analysis; NoE, no enzyme; SAM, S-adenosylmethionine.
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1. Introduction
The introduction of novel agents for the treatment of
multiple myeloma (MM), mainly proteasome inhibi-
tors and immunomodulatory agents (IMiDs), has sig-
nificantly improved the survival rates of the patients,
and both classes of drugs stand as the main treatment
options for MM (Mahindra et al., 2012). The class of
IMiDs comprises thalidomide, and its derivatives,
lenalidomide and pomalidomide, and even though
their antimyeloma activity had been confirmed in sev-
eral clinical trials, it was not until recently that their
precise mechanism of action was deciphered.
A groundbreaking study identified cereblon (CRBN)
as the direct target of thalidomide, suggesting a model
that explained the drug’s teratogenic effects (Ito et al.,
2010). Further studies have since confirmed that not
only is CRBN the direct target of thalidomide, but also
that of lenalidomide and pomalidomide, and that its
expression is required for the antimyeloma effect of
these drugs (Lopez-Girona et al., 2012; Schuster et al.,
2014; Zhu et al., 2011). CRBN has been shown to be
part of an E3 ubiquitin ligase complex (also known as
CRL4CRBN) together with CUL4A, DDB1, and RBX1,
where it serves as a substrate receptor (Angers et al.,
2006; Fischer et al., 2014). The CRBN-mediated mech-
anism of action of IMiDs is quite distinctive, as the
interaction of IMiDs with CRBN results in increased
affinity of CRBN toward novel substrates, such as the
transcription factors Ikaros (IKZF1) and Aiolos
(IKZF3), which subsequently get ubiquitinated by
CRL4CRBN and degraded in the proteasome, leading
among others to reduced expression of IRF4 in plasma
cells and increased expression of IL-2 in T cells (Fis-
cher et al., 2014; Gandhi et al., 2013a; Kr€onke et al.,
2014; Lu et al., 2013). Degradation of IKZF1 and
IKZF3 by CRBN seems, however, to be myeloma
specific, as other CRBN neosubstrates have been asso-
ciated with different diseases, such as casein kinase 1
alpha (CK1a) in myelodysplastic syndromes with the
deletion of chromosome 5q (Kr€onke et al., 2015).
Interestingly, low expression of CRBN, both at
mRNA and at protein level, has consistently been
found to be associated with a worse response to
IMiDs or even resistant/refractory disease, suggesting
a role as a potential predictive biomarker for response
to treatment to IMiDs (Broyl et al., 2013; Heintel
et al., 2013; Huang et al., 2014; Ren et al., 2015;
Schuster et al., 2014; Zhu et al., 2011). However, the
mechanisms that regulate CRBN expression still
remain elusive. It has been shown that mutations of
CRBN are infrequent in MM, thus suggesting a
potential epigenetic component (Egan et al., 2013;
Thakurta et al., 2014).
In this study, we investigated the regulation of
CRBN expression in human myeloma cell lines with
both intrinsic and acquired resistance to IMiDs. We
examined whether epigenetic mechanisms such as
DNA methylation, repressive histone marks (such as
histone lysine 27 trimethylation – H3K27me3), or
nucleosome occupancy can potentially regulate the
expression of CRBN in these cell lines. By performing
AcceSssIble together with RNA-seq, we assessed the
changes in DNA methylation and chromatin accessi-
bility, as well as gene expression, which were associ-
ated with acquired IMiD resistance. Finally, we tested
whether resensitization of resistant MM cell lines to
IMiDs is feasible through epigenetic reprogramming
by epigenetic modulators either as single agents or in
combination.
2. Methods
2.1. Cell culture and treatments
The human myeloma cell lines JJN3, OPM2, RPMI-
8226, U266, KMS12-BM, and NCI-H929 were pur-
chased from DSMZ (Leibniz Institute DSMZ–German
Collection of Microorganisms and Cell Cultures,
Braunschweig, Germany) and were grown using the
recommended cell culture medium by DSMZ, at 37 °C
with 5% CO2 in a humidified atmosphere and under
sterile conditions. Cell density and viability were deter-
mined using the cell counter NC-250 (Chemometec,
Lillerød, Denmark). For the development of IMiD-
resistant cell lines, we treated OPM2 and NCI-H929
continuously with increasing doses of either lenalido-
mide (Selleck Chemicals, Houston, TX, USA) or
pomalidomide (Selleck Chemicals) for 4–6 months,
until cell viability and proliferation were not affected,
as previously described (Lopez-Girona et al., 2012).
The starting dose of the compounds was 1 lM for
OPM2 and 0.1 lM for NCI-H929. Fresh lenalidomide
or pomalidomide was added every 2–3 days in the cell
culture and the dose was escalated in several steps (to
a final dose of 10 lM) whenever the cells consecutively
exhibited viability above 90% (as calculated by the
NC250) in the presence of the drug. The cells were not
treated with any compounds for a minimum of 7 days
before all the experiments performed in this study.
Other chemotherapeutic agents used in the cell cul-
ture in this study were 5-azacytidine (MedChem
Express, Monmouth Junction, NJ, USA) and EPZ-
6438 (MedChem Express).
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2.2. Cell proliferation and apoptosis assays
Cell proliferation was determined using the XTT Cell
Proliferation Kit II (Roche, Mannheim, Germany).
Briefly, cells were seeded in different concentrations
(between 2 9 105 and 4 9 105 cellsmL1) in 96-well
plates and were left untreated (control) or treated with
serial doses of lenalidomide and pomalidomide. Fol-
lowing incubation for 3 days, 100 lL of XTT Labeling
Reagent was added in each well, and after a further
incubation of 2–4 h, absorbance was read at 450 and
650 nm (reference wavelength). Generation of dose–re-
sponse curves and calculation of IC50 values for
lenalidomide and pomalidomide for each cell line were
performed using GRAPHPAD PRISM 6 software (Graph-
Pad Software, Inc., La Jolla, CA, USA).
For cell apoptosis, we used the FITC Annexin V
Apoptosis Detection Kit I (BD Biosciences, San Jose,
CA, USA), according to the manufacturers’ protocol.
All samples were analyzed in a FACS Calibur (BD
Biosciences). All experiments were performed in a trip-
licate and repeated at least once.
2.3. Patient samples
A total of 89 bone marrow samples were obtained from
patients with MM diagnosed with MM between 2007
and 2009, according to the IMWG criteria, at the Depart-
ment of Hematology, Rigshospitalet, Denmark. From
these samples, 48 were obtained at diagnosis and 41 at
relapse. For all the samples, the CD138+ plasma cells
were isolated from the mononuclear cell population from
each bone marrow sample with the use of a RoboSep
(Stem Cell Technologies, Vancouver, BC, Canada). All
included patients provided written consent in accordance
with the Helsinki Declaration. The Danish National Ethi-
cal Committee approved the conduction of this study.
2.4. Nucleic acid extraction
Total DNA and RNA were isolated from each cell line
using All Prep DNA/RNA/miRNA Universal kit (Qia-
gen, Hilden, Germany) according to the manufactur-
ers’ protocol. The quantity (260 nm) and quality (260/
280 and 260/230 ratios) of total DNA and RNA were
measured by spectrophotometry on a NanoDrop-1000
spectrophotometer (Thermo Scientific, Waltham, MA,
USA).
2.5. Methylation-specific melting curve analysis
(MS-MCA)
Methylation screening for the promoter of CRBN was
performed by MS-MCA as described, using 1 lg of
bisulfite-converted DNA as a template (Guldberg
et al., 2002). The primer sequences for CRBN used in
this assay were as follows: CRBN-F: 50-TGTTTAT
TAGTAAAGGAGGTTGGGATAGG-30, CRBN-R:
50-CCCTCCTAAACCATCACTTTCAAACTT-30.
The melting peaks were calculated using the LIGHT-
CYCLER 480 Software Release 1.5.0SP3. SssI-treated
DNA (Millipore, Burlington, MA, USA) and
unmethylated genomic DNA (Roche) were also bisul-
fite-converted and used as positive (methylated) and
negative (unmethylated) control, respectively.
2.6. Quantitative PCR
One microgram of RNA was reverse-transcribed using
SuperScript III First Strand Synthesis kit (Life Tech-
nologies, Carlsbad, CA, USA) according to the manu-
facturers’ instructions. Subsequently, the samples were
diluted 1 : 10 in DNase/RNase-free water and qPCR
was performed in duplicate in a 96-well format using
5 lL of cDNA and SYBR Green I Master Mix
(Roche) to a total volume of 20 lL. The PCR amplifi-
cation was carried out with the following PCR cycling
conditions: one cycle of 95 °C for 10 min, followed by
45 cycles of 95 °C for 10 s, 60 °C for 20 s, and 72 °C
for 30 s, and one cycle of 72 °C for 10 min, on a
LightCycler 480 instrument II (Roche Diagnostics).
All the qPCR primers used in this study are shown in
Table 1. Stably expressed reference genes were deter-
mined by importing Ct values transformed into a lin-
ear-scale expression quantities, and raw Ct values into
the NormFinder (Andersen et al., 2004) and GeNorm
algorithms (Vandesompele et al., 2002), respectively. A
total of 10 potential reference genes (GAPDH, ACTB,
SF3A1, PUM1, IPO8, UBC, ESP, B2M, TBP, and
HPRT1), many of which have been shown to be stably
expressed in cancer (Søes et al., 2013), were tested.
SF3A1 and PUM1 were determined as the best refer-
ence genes by both algorithms (data not shown) and
were therefore used for normalization of all qPCR
data in this study. Relative gene expression was calcu-
lated by using the comparative threshold method
(2DDCt ; Livak and Schmittgen, 2001).
2.7. Immunoblotting
Whole-cell lysates were isolated from all cell lines using
lysis buffer (RIPA buffer) with the addition of a combi-
nation of protease inhibitors [ethylenediaminete-
traacetic acid, a protease inhibitor cocktail tablet
(Roche), and phenylmethylsulfonyl fluoride]. Protein
concentration was determined by generating a 6-point
standard curve using Bradford assay in duplicate. Equal
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amounts of protein (50 lg) were then loaded to SDS/
PAGE gels, followed by transfer to a polyvinylidene
difluoride membrane. After blocking with 5% BSA in
TBS-T, membranes were incubated with the relevant
primary antibody overnight at 4 °C, washed, and incu-
bated for 1 h with a HRP-conjugated anti-rabbit sec-
ondary antibody (Abcam, Cambridge, UK). Proteins
were detected using chemical luminescence (ECL PlusTM
Chemiluminescent Detection System, Thermo Fisher
Scientific, Waltham, MA, USA). The following primary
antibodies were used in this study: rabbit polyclonal
CRBN antibody (Sigma, St. Louis, MO, USA; cat.no:
HPA-045910), rabbit polyclonal IKZF1 antibody
(Proteintech, Rosemont, IL, USA), and secondary anti-
rabbit polyclonal H3 antibody (Abcam).
2.8. Cytospin and immunohistochemical staining
Cells were harvested and washed with PBS to a con-
centration of 4–5 9 106 cellsmL1. The cells were
attached to individual slides by centrifugation of
approximately 200 lL of cell suspension at 600 r.p.m.
for 2–4 min. Following a standard procedure of fixing,
washing, and blocking the attached cells, the slides
were stained for CRBN using the HPA045910 anti-
body from Sigma, at a 1 : 1000 dilution. The stained
slides were finally microscopically evaluated and
scored independently by two hematopathologists, with
a cutoff of 30% used for CRBN positivity.
2.9. AcceSssIble assay
The principle of this assay has already been described
and published, but we slightly modified the protocol
for our cell lines (Pandiyan et al., 2013). Briefly,
500 000 cells in exponential growth phase were har-
vested and split into two microcentrifuge tubes (no
enzyme (NoE) and M.SssI reactions; 250 000 cells per
reaction), centrifuged at approximately 200 g for
5 min, and then resuspended in 60 lL PBS. For
nuclei isolation, 1 mL of lysis buffer [10 mmolL1
Tris (pH 7.4), 10 mmolL1 NaCl, 3 mmolL1
MgCl2, 0.1 mmolL1 EDTA, 0.5% NP-40] was
added, and the cells were centrifuged at approxi-
mately 700 g for 5 min at 4 °C after an incubation
of approximately 10 min on ice. The supernatant was
removed and the nuclear pellets were resuspended in
1 mL wash buffer [10 mmolL1 Tris (pH 7.4),
10 mmolL1 NaCl, 3 mmolL1 MgCl2,
0.1 mmolL1 EDTA] and centrifuged again at
3000 r.p.m. for 5 min at 4 °C. The supernatant was
removed and the following was added to each tube:
76.75 lL 19 NEB buffer 2, 7.5 lL 109 NEB buffer
2, 45 lL 1 molL1 sucrose, 5 lL 32 mmolL1 S-
adenosylmethionine (SAM), and 15 lL 4 UlL1
M.SssI (or H2O for NoE tube). The reaction mixtures
were flicked to mix and then incubated at 37 °C for
7.5 min. An additional 5 lL of SAM was added and
the samples were incubated for further 10 min. Pre-
warmed (37 °C) 300 lL Stop Solution [10 mmolL1
Tris/HCl (pH 7.9), 600 mmolL1 NaCl, 1% SDS,
0.1 mmolL1 EDTA] and 3 lL Proteinase K
(20 mgmL1) were added to each tube, and each
reaction mixture was incubated at 55 °C for 16 h.
The DNA was then purified by phenol/chloroform
extraction and ethanol precipitation and finally redis-
solved in 21 lL nuclease-free water for the subse-
quent analyses. One microgram of DNA was
Table 1. All the primer sequences used in qPCR experiments in this study.
Gene Forward primer Reverse primer
GAPDH 50-CCACTCCTCCACCTTTGACG-30 50-TGTCATACCAGGAAATGAGCTTG-30
ACTB 50-CTGGACGGTGAAGGTGACA-30 50-AAGGGACTTCCTGTAACAATG-30
SF3A1 50-TCCATCCGTGAGAAGCAGAGC-30 50-TCTGGATCTCCTCCTCACCG-30
HPRT1 50-TGACACTGGCAAAACAATGCA-30 50-GGTCCTTTTCACCAGCAAGCT-30
UBC 50-TTAGGACGGGACTTGGGTGA-30 50-CCTGTTCCGCTCTCTGGAAA-30
ESD 50-GCCTTTAGTGGATATTTGGGAACA-30 50-GGGTAGCATCATAAGCCTTCCA-30
B2M 50-TGCTGTCTCCATGTTTGATGTATCT-30 50-TCTCTGCTCCCCACCTCTAAGT-30
PUM1 50-CATGCCAGGTTATCCGGTGT-30 50-GCGCCTGCATTCACTACAAG-30
TBP 50-TGCACAGGAGCCAAGAGTGAA-30 50-CACATCACAGCTCCCCACCA-30
IPO8 50-CCTCACAACCCTGGACCTATC-30 50-ACATCTTCCGGTCATGATGC-30
CRBN 50-CCAGTCTGCCGACATCACAT-30 50-GTCATCGTGCAAAGTCCTGC-30
IKZF1 50-ACAGCAAAGCTCCAAGAGTGA-30 50-TCCCCATTCATTTCACAGGCA-30
IKZF3 50-TGTTTATTAGTAAAGGAGGTTGGGATAGG-30 50-CCCTCCTAAACCATCACTTTCAAACTT-30
IRF4 50-CCTTTTATGCTTGTGCCCCA-30 50-GTCAGCTCCTTCACGAGGATT-30
ACTB (AcceSssIble) 50-AGAGGGGGTAAAAAAATGTTGTAT-30 50-TCGAACCATAAAAAACAACTTTC-30
C1D (AcceSssIble) 50-TTTTTGGAGAAGAGTTAAGGAGTAGG-30 50-ACTCCAATCTCCCGAAAAAC-30
GRP78 (AcceSssIble) 50-AGATAGTTGTTGAATTAATGGGATT-30 50-CCCCCCAACTAATTCATTAACTA-30
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bisulfite-converted using the Zymo EZ DNA Methy-
lation Kit, and subsequent quality control of M.SssI
treatment was performed as previously described
(Becket et al., 2016), using ACTB, C1D, and GRP78
as controls. The primer sequences are given in
Table 1.
2.10. ChIP assay
For ChIP, we harvested 1 9 107 exponentially growing
cells, fixed them at room temperature using 1%
formaldehyde, and then sonicated the fixed cells for
30 s with 30 s of pause on ice, for a total of nine
cycles. Chromatin size was tested by running the DNA
in a 1.5% agarose gel, and protein content was quanti-
fied using Bradford assay. The samples were then incu-
bated with the desired primary antibody and beads
overnight at 4 °C. After washing and de-cross-linking
the following day, DNA was purified using PCR col-
umns (Qiagen), diluted 1 : 2, and then qPCR was per-
formed in duplicate, normalizing to a biological
duplicate of total input.
2.11. Genome-wide methylation and chromatin
accessibility analysis
The Infinium HumanMethylationEPIC BeadChip
array (Illumina, Inc., San Diego, CA, USA), contain-
ing a total of 866 836 probes, was used to analyze gen-
ome-wide DNA methylation patterns. Data import
and analysis, normalization, background and dye bias
correction, and calculation of b values were performed
using the R package minfi (Fortin et al., 2016). Probes
containing a SNP (N = 340 327), cross-reactive probes
(N = 42 558) (both based on McCartney et al. (2016)),
probes located on the sex chromosomes (N = 19 681),
and probes with a high detection P-value (above 0.01)
were filtered before further analyses, leaving a total of
522 554 probes.
Accessibility for each cell line (Acc) was defined as
the difference between the corrected b-values (range 0–
1) of the M.SssI-treated sample and of the NoE sam-
ple (endogenous methylation values for each CpG
locus). After removing negative values of Acc for each
cell line, Acc and NoE values of every resistant cell
line were then subtracted from their respective values
in their sensitive counterpart, resulting in delta-methy-
lation (DMeth) and delta-accessibility (DAcc) values.
DMeth and DAcc values (Db values) were used in the
subsequent analyses as values for changes in DNA
methylation and accessibility upon acquired IMiD
resistance, using a cutoff of Db value  0.20 for
changes at each locus.
2.12. Transcriptome analysis
A total of 1 lg of RNA was used for RNA-seq. We
sequenced ten cell lines (IMiD-sensitive OPM2 and
NCI-H929, their IMiD-resistant counterparts, and the
resensitized cells after 48 h of treatment with 5-azacyti-
dine and EPZ-6438), all in technical duplicate, leaving
a total of 20 samples. The sample quality control,
library preparation and quality control, sequencing,
and data quality control were performed by BGI.
Briefly, library preparation was performed using
oligo-dT beads for enrichment with mRNA containing
poly-A tails. RNA was then fragmented and reverse-
transcribed to double-stranded cDNA (dscDNA) using
random hexamer primers. Each library was then
sequenced at a depth of 20M clean reads using SE50
sequencing on the BGISEQ500 platform. The dscDNA
was then end-repaired and ligated to the bubble adap-
ter with protruding T of 30 end. During PCR amplifi-
cation step, the fragments were separated into single
strands, amplified, and cyclized to form ‘DNA nano-
balls’, which were finally sequenced at a depth of 20M
clean reads.
2.13. Transcriptome data analysis
RNA-seq data were aligned to the human reference
genome (GRCh37/hg19) using Tophat, as part of the
cufflinks pipeline. Aligned reads were then assembled
into transcripts and quantified using the cufflinks pipe-
line (Trapnell et al., 2012). Raw transcript counts, as
produced by the cuffnorm step of cufflinks, were then
processed using the R package DESeq2 in order to
discover differentially expressed genes across sample
groups. Differential expression was determined without
the use of a Cooks cutoff, and differentially expressed
genes were considered significant based on both their
fold change (absolute value of log2-fold change above
1) and their adjusted P-value using the Benjamini–
Hochberg method (P < 0.05).
2.14. Statistical analysis
All the statistical analyses and calculations for AcceSs-
sIble and RNA-seq were performed in the statistical
software R (version 3.3.1, https://www.r-project.org/).
Comparison of mean values across different subgroups
was made by ANOVA (making the assumption that
the data were normally distributed for each group),
with the analyses performed in GRAPHPAD PRISM 6.
When multiple comparisons were made, the P-values
were corrected with the Bonferroni method. The level
for significance was set at 0.05 with the following
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annotation: *P < 0.05, **P < 0.01, ***P < 0.001, and
****P < 0.0001.
3 Results
3.1. Cereblon is downregulated in acquired IMiD
resistance
First, we tested the sensitivity of all the cell lines to
both lenalidomide and pomalidomide by generating
dose–response curves and calculating the IC50 of both
drugs for each cell line. Using the two most IMiD-sen-
sitive cell lines, namely OPM2 and NCI-H929, we were
able to generate lenalidomide- and pomalidomide-
resistant cell lines (OPM2-LR, OPM2-PR and
NCI-H929-LR, NCI-H929-PR, respectively) by contin-
uously culturing the cells in the presence of IMiDs for
a period of 4–6 months (Fig. S1A,B). Consistent with
previously published data, we observed a significant
reduction in CRBN expression in all four IMiD-resis-
tant cell lines when compared with their sensitive
counterparts at mRNA level, using qPCR primers
including exons 8 and 9 (Fig. 1A) and exons 10 and
11 (the IMiD-binding region of CRBN – data not
shown), both producing similar results. For the protein
expression of CRBN, we performed western blotting,
as well as immunohistochemical staining for CRBN
for the cell lines. We observed a decrease in the pro-
tein expression of CRBN in IMiD-resistant cell lines
using both methods, consistent with the reduction in
mRNA levels (Fig. 1B,C). No significant expression
changes in IKZF1, IKZF3, or IRF4 were observed
(data not shown).
3.2. Cereblon expression is not regulated by
promoter methylation
Previous studies have shown that mutations in the
coding sequence of CRBN are rare. In addition, in
agreement with previous studies, we observed a strong
downregulation of CRBN mRNA expression in IMi-
D-resistant cell lines, suggesting that the major mecha-
nism of IMiD resistance is caused by reduced
transcription of CRBN. Therefore, we hypothesized
that epigenetic silencing through promoter hyperme-
thylation might be a possible mechanism explaining
the downregulation of CRBN in the IMiD-resistant
cell lines. Using MS-MCA, we tested all the cell lines
used in this study, as well as a total of 48 patients with
newly diagnosed MM and 41 patients with relapsed
MM. None of the cell lines, sensitive or resistant, and
none of the patient samples showed hypermethylation
of the promoter area of CRBN (Fig. 2A and Fig. S1).
Thus, these data suggest that the proximal promoter
of CRBN is consistently unmethylated and variations
in its expression are not caused by changes in DNA
methylation.
3.3. Cereblon promoter retains active histone
marks and remains nucleosome-depleted in
IMiD-resistant cell lines
After having excluded DNA methylation as a potential
epigenetic regulatory mechanism of CRBN expression,
we examined whether the promoter of CRBN exhib-
ited either an increase in the repressive histone mark
H3K27me3, or an increase in nucleosome occupancy
in the IMiD-resistant cell lines. By performing ChIP
for the genomic area around the transcription start site
(TSS) of CRBN, we observed that in both OPM2- and
NCI-H929 IMiD-resistant cells, that area maintained
enrichment of histone marks associated with active
transcription (H3K4me3, H3K27Ac) and was depleted
of H3K27me3 (Fig. 2B,C).
Furthermore, using AcceSssIble, we compared both
the genome-wide DNA methylation and chromatin
accessibility changes between OPM2 and NCI-H929
and their IMiD-resistant counterparts. The assay cov-
ered (after filtering irrelevant probes – see Methods) a
total of five probes for CRBN with four in the pro-
moter area (200 bp upstream of the transcription start
site) and one in the first exon of CRBN gene. Confirm-
ing our previous results, none of these probes exhib-
ited changes in methylation levels between the sensitive
and resistant cell lines (data not shown). Even more
interestingly, none of the probes showed significant
decreases in chromatin accessibility, with all DAcc val-
ues for all probes being higher than the cutoff of
0.20 (Fig. 2D). Overall, these data suggest that the
proximal promoter of CRBN is in an active conforma-
tion and that the expression of CRBN is not influ-
enced by epigenetic mechanisms (DNA methylation,
histone modifications, nucleosome occupancy) but
probably through other cis or trans regulatory
mechanisms.
3.4. Acquired resistance to IMiDs is associated
with global changes in DNA methylation and
chromatin accessibility
Using AcceSssIble, we were able to compare the com-
bined chromatin accessibility and methylation changes
between IMiD-sensitive cell lines for a total of 522 554
probes across the genome. Interestingly, we found that
acquired resistance for both lenalidomide and poma-
lidomide in OPM2 was primarily associated with a
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global decrease in chromatin accessibility and to a
much lesser extent with DNA methylation changes
(Fig. 2E). However, NCI-H929 IMiD-resistant cells
exhibited a slightly different pattern, with a combined
increase in DNA methylation and decrease in chro-
matin accessibility (Fig. 2F). Slightly less than half of
these changes occurred in promoter areas of known
genes (Fig. S2A). Interestingly, none of the other
molecules involved in the CRBN pathway (IKZF1,
IKZF3, IRF4) exhibited changes in either promoter
DNA methylation or chromatin accessibility, which
was not surprising, as their expression remained
NCI-H929  
x400
NCI-H929-LR  
x400
NCI-H929-PR  
x400
OPM2 
x400
OPM2-LR 
x400
OPM2-PR 
x400)
CRBN
H3
OPM2 OPM2-LR OPM2-PRH929-LR H929-PRH929
A
B
C
Fig. 1. (A) qPCR results of the CRBN expression across the IMiD-sensitive cell lines (OPM2, NCI-H929: dark bars on the left and right plot,
respectively) and their lenalidomide- and pomalidomide-resistant counterparts (dark gray and light gray bars, respectively). There is a
significant downregulation of CRBN mRNA in all four cell lines with acquired IMiD resistance, compared to the parental, sensitive cell lines.
**P < 0.01, ***P < 0.001, and ****P < 0.0001.(B) Western blot for CRBN, confirming the reduction in CRBN expression at protein level in
loss of IMiD sensitivity. (C) Cytospin and immunohistochemical staining for CRBN in OPM2, NCI-H929, and their IMiD-resistant
counterparts, confirming the significant reduction in CRBN expression in the resistant cells.
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unchanged upon acquired IMiD resistance. Thus, these
data suggest that resistance to IMiDs is associated
with extensive epigenetic reprogramming that includes
changes in chromatin accessibility and DNA methyla-
tion, but these events do not directly involve the core
components of the CRBN pathway.
3.5. Acquired resistance to IMiDs is potentially
reversible with epigenetic therapy
As epigenetic modifications have been shown to be
druggable and potentially reversible, we next examined
whether it was possible to restore normal levels of chro-
matin accessibility and/or DNA methylation of impor-
tant regulatory genomic areas by treatment with a panel
of epigenetic modulators: a DNA methyltransferase
inhibitor (5-azacytidine), an HDAC inhibitor (panobi-
nostat), and an EZH2 inhibitor (EPZ-6438), tested both
as monotherapy and in different combinations. All
IMiD-resistant cell lines were treated with different
doses and combinations of these epidrugs for 48 h and
then exposed to either no further treatment (control) or
10 lM lenalidomide or pomalidomide for an additional
period of 3 days, after which we evaluated the resensiti-
zation effect by measuring apoptosis. Using OPM2-PR
as a model, we found that the most effective resensitiza-
tion epigenetic therapy was the combination of 5-azacy-
tidine (5-Aza) and EPZ-6438, with panobinostat and
EPZ-6438 as the second most effective (Fig. S2B). Fur-
ther examining the potential of this combination, we
found that exposure to the combination of 5-Aza and
EPZ-6438 for 48 h could effectively resensitize IMiD-
resistant cells with an apoptotic response very similar to
the original, IMiD-sensitive cells (Fig. 3A). The combi-
nation of 5-Aza and EPZ-6438 could effectively resensi-
tize all four cell lines with acquired IMiD resistance,
albeit the dose of 5-Aza should be increased to 0.5 lM
in the case of NCI-H929-LR and NCI-H929-PR for the
combination to be effective, which is in line with our
previous finding that NCI-H929 cells exhibit more
DNA methylation changes upon acquiring resistance to
IMiDs (Fig. S2C). Even more interestingly, we found
that the treatment with 5-Aza and EPZ-6438 almost
completely restored the majority of the global chro-
matin accessibility changes associated with IMiD resis-
tance back to the initial state, even though the same was
not observed for DNA methylation changes (Fig. 3C,
Fig. S2D). Overall, these data suggest that acquired
resistance to IMiDs is mainly associated with a global
epigenetic reprogramming affecting both chromatin
accessibility and DNA methylation, and can potentially
be restored by simultaneously inhibiting DNA methyla-
tion and EZH2.
3.6. Transcriptome changes in IMiD-resistant cell
lines are mainly characterized by gene
downregulation
In order to examine whether the observed changes in
chromatin accessibility and DNA methylation across
the IMiD-resistant cell lines coincide with aberrant
gene expression patterns, we performed RNA-seq anal-
ysis in the sensitive, resistant, and resensitized cell
lines. We found that IMiD-resistant cell lines indeed
exhibit altered global gene expression – primarily
downregulation (Fig. S3A,B), consistent with the epi-
genetic changes we observed in these cells with a pre-
dominance of reduced chromatin accessibility and
increased DNA methylation. Interestingly, the overlap
of known genes with significantly increased DNA
methylation and/or reduced chromatin accessibility
and of genes with reduced gene expression in the resis-
tant cell lines was rather small (Fig. 3C). When we iso-
lated the genes whose expression was restored after
treatment with 5-Aza and EPZ-6438, we identified
SMAD3 as a commonly downregulated gene across all
four IMiD-resistant cell lines with subsequent upregu-
lation and normalization of expression after epigenetic
resensitization (Fig. 3D). Overall, our data suggest
that acquired IMiD resistance is also associated with
global gene expression changes, although in a lesser
degree than epigenetic changes, and identify SMAD3
as a gene whose expression might play a significant
role in the sensitivity of plasma cells to IMiDs.
3.7. Resensitization to IMiDs is independent of
CRBN
As the resistant cell lines exhibited a significant decrease
in CRBN expression potentially due to the observed
genome-wide increase in nucleosome occupancy, we
decided to examine whether the combination of 5-Aza
and EPZ-6438 was able to restore the levels of CRBN
expression back to normal. As expected, monotherapy
with each of the drugs failed to result to an increase in
CRBN expression (Fig. 4A). However, more interest-
ingly, we observed that treatment with the combination
of 5-Aza and EPZ-6438 also failed to induce a signifi-
cant upregulation of CRBN, thus suggesting that the
process of resensitization to IMiDs might be CRBN
independent. Furthermore, we found that degradation
of IKZF1, 24 h after treatment with either lenalidomide
or pomalidomide, was abrogated in OPM2-PR, but
was partly restored after the cells were treated with 5-
Aza and EPZ-6438 (Fig. 4B). This finding not only
confirms that degradation of IKZF1 might be essential
for the antimyeloma effect of IMiDs, but also suggests
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Illumina ID Location ΔAcc H929-LR ΔAcc H929-PR ΔAcc OPM2-LR ΔAcc OPM2-PR
cg11116142 1st Exon –0.0138 –0.0362 –0.1114 –0.1247
cg16797762 Promoter –0.1329 0.0148 –0.0420 0.0068
cg18729488 Promoter 0.0584 0.0551 –0.1565 –0.1491
cg12609739 Promoter 0.0442 –0.0532 –0.2052 –0.1683
cg09463755 Promoter 0.0043 0.0006 –0.0587 –0.0667
Melting peaks
–(
d/
dT
) F
lu
or
es
ce
nc
e
(4
65
- 5
10
)
Temperature (°C)
A
B
D
E
F
C
188 Molecular Oncology 12 (2018) 180–195 ª 2017 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
Epigenetic resensitization to IMiDs K. Dimopoulos et al.
OPM2/No pretreatment
Len. 10 μM Pom. 10 μMUntreated
OPM2-PR/No pretreatment
Len. 10 μM Pom. 10 μMUntreated
OPM2-PR/5-Aza + EPZ-6438
Len. 10 μM Pom. 10 μMUntreated
An
ne
xi
n
V
Propidium Iodide (PI)
A B
C
Fig. 3. (A) Apoptosis results for OPM2, OPM2-PR, and resensitized OPM2-PR. The original OPM2 cells are sensitive to both lenalidomide
and pomalidomide, where treatment with 10 lM of either compound led to an apoptotic response after 72 h. In contrast, both drugs fail to
induce apoptosis in the pomalidomide-resistant OPM2-PR cells. However, after epigenetic pretreatment with 5-Aza (0.1 lM) and EPZ-6438
(10 lM) for 48 h and subsequent treatment with either lenalidomide or pomalidomide for 3 days, the apoptotic response to the drugs was
restored. (B) Apoptosis measurements for OPM2-PR without any pretreatment (black bars), with pretreatment only with 0.1 lM of 5-Aza
(green bars), with EPZ-6438 (blue bars), and with both (red bars). Even though both 5-Aza and EPZ-6438 have a slight resensitizing effect as
monotherapy, the combination is significantly more effective in restoring IMiD sensitivity to OPM2-PR cells. *P < 0.05, **P < 0.01, and
***P < 0.001. (C) Heatmaps with all the probes exhibiting either accessibility changes (N = 6844, upper heatmap in blue/yellow) or DNA
methylation changes (N = 2102, bottom heatmap in red/green) in OPM2-PR when compared with OPM2. The majority of the probes
(approximately 80%) that exhibited altered chromatin accessibility restored their initial accessibility values after 48 h of treatment with 5-Aza
and EPZ-6438, while the acquired DNA methylation patterns in the resistant cells were more stable.
Fig. 2. (A) Methylation-specific melting curve analysis for the IMiD-sensitive and IMiD-resistant cell lines, showing the absence of promoter
DNA methylation of CRBN. The blue curves are the fully unmethylated and fully methylated controls (left and right curve, respectively), and
the green lines represent the cell samples. (B, C) ChIP for H3K4me3, H3K27Ac, and H3K27me3 around the transcription site of CRBN for
OPM2 and NCI-H929, respectively, revealed that IMiD-resistant cell lines retained their activating histone marks (H3K4me3, H3K27Ac)
without any significant increase in the repressive mark H3K27me3. (D) Chromatin accessibility values for the probes mapping to CRBN,
assessed with AcceSssIble. The difference in the accessibility of the resistant cell lines compared with their parental cell line (DAcc) was
calculated by subtracting the accessibility value of the paternal cell line from the accessibility value of the resistant cell line for each
individual probe. None of the probes covering CRBN showed significant accessibility changes in any of the IMiD-resistant cell lines. (E, F)
Kernel density plot of the combined DNA methylation changes and chromatin accessibility changes observed in the IMiD-resistant cell lines.
The OPM2 IMiD-resistant cells exhibit primarily a decrease in the global chromatin accessibility when compared with the parental OPM2
(E), while H929 IMiD-resistant cell lines exhibit a pattern of combined loss of chromatin accessibility with increased DNA methylation (F).
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that low expression of CRBN does not necessarily
translate to reduced sensitivity to IMiDs.
3.8. Intrinsic resistance to IMiDs is potentially
also reversible through EZH2 inhibition
Even though intrinsic resistance to IMiDs is probably
biologically distinctive from acquired resistance, we
tested the resensitizing efficacy of 5-Aza and EPZ-6438
in eight primary resistant or partly resistant IMiDs cell
lines: JJN3, RPMI-8226, U266, KMS12-BM, MOLP2,
MOLP8, LP1, and EJM. We found that 5-Aza (doses
ranging from 0.1 to 0.5 lM) and EPZ-6438 (doses
ranging from 1 to 10 lM) in combination significantly
increased the sensitivity of cells to both lenalidomide
and pomalidomide in seven of eight cell lines (Fig. 4C
and Fig. S4). The only cell line that remained resistant
after epigenetic pretreatment was U266, which is
known to carry a multidrug-resistant phenotype. How-
ever, as a reflection of the differential mechanisms that
govern intrinsic IMiD resistance, a proportion of the
resistant cell lines obtained a similar degree of IMiD
sensitivity with EZH2 inhibition alone, possibly sug-
gesting that primary resistance to IMiDs might be
epigenetically less complex and potentially easier to
overcome.
4. Discussion
The discovery of CRBN as the direct biological target
of all IMiDs has led to a deeper understanding of their
complex mechanism of action. Early data underscored
the essential role of CRBN for response to IMiDs, as
cell lines with abrogated expression of CRBN lost their
sensitivity to the compounds (Lopez-Girona et al.,
2012; Zhu et al., 2011). Further research has suggested
that CRBN might be a predictive biomarker of response
to IMiDs (Broyl et al., 2013; Heintel et al., 2013;
Huang et al., 2014; Ren et al., 2015). However, lack of
standardized techniques for the precise measurement of
CRBN expression and broad biological variability, such
as multiple transcript isoforms with potentially different
roles, might explain why CRBN expression is not used
as a biomarker in clinical praxis yet. In the study by
Gandhi et al. (2013b), baseline expression of CRBN
was not found to be associated with responsiveness to
IMiDs and a reduced expression of CRBN was only
observed during acquired loss of sensitivity to IMiDs.
A B
C
Fig. 4. (A) The expression of CRBN at mRNA level was not restored after treatment of the resistant cells with 5-Aza, EPZ-6438, or their
combination, suggesting that the downregulation of CRBN, which is observed in all the IMiD-resistant cells with acquired resistance, might not
have a direct causality to the development of resistance. (B) Western blot of IKZF1 in OPM2, OPM2-PR, and OPM2-PR cells after treatment
with 5-Aza and EPZ-6438. All the cells were either untreated or treated with lenalidomide or pomalidomide (10 lM) for 24 h, at which point cell
lysates were isolated. The CRBN-dependent degradation of IKZF1 after treatment with IMiDs is reduced in OPM2-PR, but is partly rescued in
the resensitized OPM2-PR cells. (C) Apoptosis response in primary IMiD-resistant cell lines JJN3, LP1, and RPMI-8226, showing that the
combination of 5-Aza and EPZ-6438 – or EZH2 inhibition alone (in the case of JJN3), can also overcome intrinsic resistance to IMiDs.
**P < 0.01, ***P < 0.001, and ****P < 0.0001.
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Our data confirmed this finding, as we observed a signif-
icant decrease in both mRNA and protein levels of
CRBN in cell lines with acquired resistance to lenalido-
mide and pomalidomide, achieved through prolonged
exposure to the agents. Interestingly, baseline levels of
CRBN or any of its downstream targets did not seem to
be associated with IMiD sensitivity of the cell lines used
in this study, thus again questioning the predictive role
of CRBN to IMiD responsiveness.
The regulatory mechanisms that govern the expres-
sion of CRBN have not yet been discovered. Early
studies using NGS-based methods showed that muta-
tions of the CRBN-coding sequence are rare in MM
(Egan et al., 2013; Thakurta et al., 2014). However, a
more recent study by Kort€um et al. (2016), using tar-
geted sequencing in a cohort of 50 relapsed/refractory
MM patients, found a 12% (6/50) frequency of CRBN
mutations, some of which affected the IMiD-binding
domain in exons 10–11. To uncover a possible epige-
netic component in the regulation of CRBN, we
assessed DNA methylation, histone modifications, and
nucleosome positioning of the proximal promoter area
of CRBN, and showed that CRBN is not directly reg-
ulated by any of them, but likely by other cis or trans
regulatory elements.
Using AcceSssIble, a method that allows measure-
ment of the global levels of both DNA methylation
and chromatin accessibility, we showed that acquired
IMiD resistance was accompanied by global epigenetic
changes in form of decreased chromatin accessibility
and increased DNA methylation. It must be men-
tioned here that AcceSssIble is limited by the probe
coverage that Illumina EPIC assay offers (approxi-
mately 500 000 probes after filtering), which means
that it does not offer information about the entire gen-
ome. However, it is still a high-throughput, but at the
same time cost-effective and bioinformatically manage-
able method, covering the most important regulatory
genomic areas, such as gene promoters and enhancers.
Chromatin accessibility has consistently been shown
to affect gene expression (Portela and Esteller, 2010).
In a more recent study, it was shown to be even more
cell type specific than gene expression and changes in
accessibility were most prominent in disease-specific
cells in both benign and malignant diseases (Corces
et al., 2016). In our study, we find that chromatin
accessibility might play an important role in drug
resistance, a finding that requires further investigation,
but which is of extreme interest, as epigenetic modifi-
cations are potentially reversible.
Drugs that modify the epigenome, such as 5-azacyti-
dine or panobinostat, have already been approved for the
treatment of some hematological malignancies (high-risk
myelodysplastic syndromes and MM, respectively).
Despite the impressive in vitro efficacy of both 5-azacyti-
dine and HDAC inhibitors in MM, shown in several
studies (Kiziltepe et al., 2007; Maiso et al., 2006; Ocio
et al., 2010; Sanchez et al., 2011; Tian et al., 2013), their
performance in clinical studies, when used as monother-
apy, has been quite disappointing. Importantly, both
classes of drugs are not as cytotoxic as traditional
chemotherapeutic agents, but when used in low doses
alone or in combination, might ‘prime’ the epigenome
and enhance sensitivity to other, more toxic compounds.
In another interesting finding, we were able to inverse
chromatin accessibility with a combination of 5-azacyti-
dine and EPZ-6438 and restore sensitivity to both
lenalidomide and pomalidomide in all four cell lines with
acquired IMiD resistance. This combination was shown
to almost entirely reverse the chromatin accessibility to
the initial state and restore sensitivity, and interestingly,
it was shown to be effective in inducing apoptosis inde-
pendently of CRBN expression. This is, to our knowl-
edge, the first report on combined DNA methyl
transferase 1 (DNMT1) and EZH2 inhibition and its
effects on epigenetic reprogramming and drug resistance.
The justification for this combination is extensively
supported by previous data. In a study from our group,
we showed that decreased chromatin accessibility in
malignant cells (with a concomitant decrease in gene
expression) was only partly associated with increased
DNA methylation on the same probes, suggesting that
the probes without DNA methylation most possibly
obtain the repressive H3K27me3 histone mark (Becket
et al., 2016). Another study showed that malignant cells
can have almost double as many combined DNA
methylation and H3K27me3 silencing marks, as com-
pared to normal cells (Takeshima et al., 2014), further
supporting treatment strategies that combine inhibition
of DNMT1 and EZH2. Finally, patients with myelodys-
plastic syndromes (MDS) presenting with monosomy 7
(where EZH2 is located) or inactivating point mutations
of EZH2 respond better to treatment with 5-azacytidine,
suggesting that dual inhibition of EZH2 and DNA
methylation might be more effective in these patients
(Tobiasson et al., 2016).
Global gene expression analysis of IMiD-resistant
cell lines showed a dominance of gene downregulation,
consistent with the results from AcceSssIble that
showed a tendency toward increased DNA methyla-
tion and decreased chromatin accessibility, both of
which are known to repress gene expression. However,
the overlap between the epigenetically affected genes,
discovered by AcceSssIble, and the deregulated genes
by RNA-seq was rather little. The lack of direct corre-
lation of epigenetic aberrations and gene expression
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could be due to the existence of noncoding genomic
regions in the Illumina array, some of which might
have important regulatory abilities. Furthermore, the
lack of inhibitory epigenetic marks such as DNA
methylation or nucleosome occupancy is permissive
for, but does not alone cause gene expression, which
also requires, for example, the relevant transcription
factors. Finally, the Illumina probes that cover known
genes do not only cover proximal regulatory areas
such as promoters, but might also cover areas such as
first exons or 30-UTR, which possibly not directly
affect the expression of their corresponding gene.
The finding that SMAD3 is commonly downregu-
lated and subsequently upregulated by the combination
therapy in all the cell lines with acquired IMiD resis-
tance is interesting. Even though SMAD3 has not so
far been directly associated with the CRBN pathway, it
is a well-known transcriptional regulator and a core
component of the canonical transforming growth fac-
tor beta (TGF-b) signaling pathway (Millet and Zhang,
2007). It has been shown that TGF-b has an ambigu-
ous role in tumorigenesis, enabling both growth inhibi-
tion, especially in early stages of carcinogenesis, and
tumor growth in latter stages (Massague, 2008).
Accordingly, SMAD3 has been found to have both
oncogenic and tumor suppressor roles in cancer. It has
been shown that high expression of SMAD3 is essential
for the tumor suppressive effects of TGF-b, while lower
expression levels are associated with the tumor-promot-
ing effect of TGF-b (Daly et al., 2010). Even more
interestingly, the same study showed that the levels of
SMAD3 were controlled by the Ras pathway, members
of which are frequently mutated in MM (Chapman
et al., 2011). Further supporting the tumor suppressor
role of SMAD3, its downregulation has been associated
with acute T-cell lymphoblastic leukemia, as well as
gastric cancer (Han et al., 2004; Wolfraim et al., 2004).
In addition, activation and recruitment of SMAD3 to
the nucleus upon TGF-b induction has been found to
induce the cell cycle regulator p21WAF1 and downregu-
late c-MYC (Alexandrow et al., 1995; Frederick et al.,
2004), which also happen to be the end-targets of
IMiDs (Escoubet-Lozach et al., 2009; Lopez-Girona
et al., 2011; Verhelle et al., 2007). A possible model
might be that IMiD-resistant plasma cells escape the
antitumor effects of TGF-b and gain a proliferation
advantage by downregulating SMAD3. Otherwise, it
might also be likely that the SMAD3-dependent TGF-b
signaling is required for the IMiD-induced downregula-
tion of MYC and induction of p21WAF1 and its abroga-
tion through downregulation of SMAD3 might reduce
the effectiveness of IMiDs. However, the precise biolog-
ical role of SMAD3 in IMiD resistance in myeloma
and its potential use as a biomarker of responsiveness
to IMiDs require further investigation.
The fact that the epigenetically induced IMiD resen-
sitization is CRBN independent is intriguing; this
might suggest that there are other direct targets for
IMiDs, or it might question the role of CRBN down-
regulation in acquired IMiD resistance. Based on our
current data, it is unlikely that CRBN downregulation
is a ‘driver’ event for resistance, but rather a secondary
effect of the global genomic reprogramming during the
drug resistance process. Furthermore, this also means
that even if acquired IMiD resistance is in some cases
caused by mutations of CRBN (e.g., in the IMiD-
binding domain, as mentioned above), bypassing
CRBN through epigenetic reprogramming might over-
come the effect of these mutations. However, the pre-
cise mechanism through which this combination can
effectively restore IMiD sensitivity has to be further
inquired, as a better understanding of the complexity
of the CRBN pathway and IMiD interactions may
unravel novel biological targets for therapy.
In conclusion, our study is the first to ever show
that acquired IMiD resistance is mainly an epigenetic
event that is potentially reversible through a combina-
tion of two epigenetic compounds, 5-azacytidine and
EPZ-6438. These drugs have been shown to have rela-
tively low levels of toxicity, thus making them very
good candidates for a prospective phase I study to
examine their potential as ‘IMiD resensitizers’, which
may improve the outcome of treatment of MM
patients with drug-resistant myeloma clones and a
potentially high-risk disease.
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Fig. S1. (A, B) Dose-response curves for lenalidomide
and pomalidomide in (A) OPM2 and (B) NCI-H929,
as well as their resistant counterparts. (C, D) Methyla-
tion specific melting curves for the CRBN promoter of
CD138+ plasma cells from (C) 48 patients with newly
diagnosed MM and (D) 41 patients with relapsed
MM. The blue curves represent the unmethylated
(left), methylated (right) and 50% methylated (bi-
modal) controls, while the green curves, which all fall
under the unmethylated control, represent the DNA
samples from the patients. The promoter of CRBN
was unmethylated in all the patients analyzed in this
study.
Fig. S2. (A) Proportional genomic distribution (pro-
moters vs non.promoter areas) of all the probes with
accessibility or DNA methylation changes across all
IMiD-resistant cell lines. A bit less than half of the
probes showing significant changes in either accessibility
or DNA methylation in the resistant cell lines map to
promoter areas of known genes. (B) Apoptosis response
of OPM2-PR to either no treatment or 10 lM of
lenalidomide or pomalidomide for 72 h, followed by a
48 h pretreatment with different epigenetic drugs. The
most effective combination in restoring the apoptotic
effect of IMiDs to the resistant OPM2-PR cells was 5-
Azacytidine and EPZ-6438. (C) Apoptotic response of
H929-PR without any pretreatment (black bars), with
pretreatment only with 0.5 lM of 5-Aza (green bars),
with EPZ-6438 (blue bars) and with both (red bars).
The combination of 5-Aza and EPZ-6438 is effective in
resensitizing the H929-IMiD-resistant cells in a similar
manner to OPM2-LR and OPM2-PR. (D) Kernel den-
sity scatter plot of the accessibility changes (x axis) and
DNA methylation changes (y axis) in OPM2-PR trea-
ted with 5-Aza and EPZ-6438 for 48 h, compared to
the paternal OPM2. The cluster of probes exhibiting
decreased accessibility observed in OPM2-PR (Fig. 2E)
is significantly decreased, with more probes showing
increased accessibility and decreased methylation.
Fig. S3. (A, B) Volcano plots of differentially expressed
genes for OPM2-PR (A) and H929-PR (B) compared
to their paternal cell lines. The dots in red represent the
differentially expressed genes with an absolute value of
log2 fold change above 1 and an adjusted P-value (Ben-
jamini–Hochberg method) below 0.05. There is a slight
predominance of downregulated genes in both cases,
supporting the data from AcceSssIble. (C) Venn dia-
gram of all the Illumina probes mapping to known
genes showing either decreased accessibility or increased
DNA methylation in OPM2-PR and all the downregu-
lated genes found in RNA-seq of OPM2-PR, showing
only little/some overlap between epigenetic deregulation
and gene expression. (D) Expression pattern of
SMAD3 in OPM2 (IMiD sensitive), OPM2-LR and
OPM2-PR (IMiD resistant) and the epigenetically
resensitized OPM2-LR and OPM2-PR, shown in nor-
malized counts for gene length (fpkm: Fragments Per
Kilobase of transcript per Million mapped reads).
SMAD3 follows the same expression pattern in the
H929 sensitive, resistant and resensitized cell lines.
Fig. S4. Apoptosis measurements in five primary IMiD-
resistant or partly resistant cell lines: KMS12-BM,
MOLP2, EJM, MOLP8 and U266.
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